Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER vs ANDROID 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mannitol is an osmotic diuretic that increases plasma osmolality, drawing water from intracellular spaces into the extracellular fluid and bloodstream, thereby reducing cerebral edema and promoting diuresis. Dextrose provides a source of calories and may help prevent hypoglycemia.
Android 25 contains methyltestosterone, a synthetic androgen that binds to androgen receptors, promoting protein synthesis and anabolic effects. It also inhibits gonadotropin secretion from the pituitary, reducing endogenous testosterone production.
Reduction of intracranial pressure,Reduction of intraocular pressure,Promotion of diuresis in oliguric acute renal failure (prophylaxis or treatment),Osmotic diuresis for drug overdose (e.g., salicylates, barbiturates),Irrigation solution during transurethral prostatic resection
Hypogonadism in males (primary and secondary),Delayed puberty in males,Metastatic breast cancer in women (as palliative therapy)
Adult: 50-100 g (500-1000 m L of 10% solution) intravenously over 1-2 hours, repeated as needed every 6-12 hours. Individualize based on urine output and serum osmolality.
Testosterone 25 mg subcutaneously or intramuscularly every 2 to 4 weeks. Alternatively, 125 mg intramuscularly every 10 days.
Terminal elimination half-life of mannitol is approximately 1.5-2 hours in patients with normal renal function. Clinically, duration of osmotic diuresis parallels half-life; in renal impairment, half-life may extend to 24-36 hours, increasing risk of fluid overload and electrolyte disturbances.
Terminal elimination half-life: 10–100 minutes (testosterone); clinical context: rapid clearance necessitates frequent dosing or use of esters for sustained effect
Mannitol is not significantly metabolized; it is excreted unchanged by the kidneys. Dextrose is metabolized via glycolysis to pyruvate and lactic acid, and enters the Krebs cycle for energy production.
Primarily hepatic via reduction and oxidation; metabolites include androsterone and etiocholanolone; excreted in urine.
Primarily renal excretion: Mannitol is filtered by glomeruli and not reabsorbed, excreted unchanged in urine (approximately 80-90% within 24 hours). Biliary/fecal elimination is negligible (<5%). Dextrose is metabolized to CO2 and water; any excess is excreted renally as glucose if threshold exceeded.
Renal: 90% (as glucuronide and sulfate conjugates, 5–10% unchanged); fecal/biliary: 10%
Mannitol is not significantly bound to plasma proteins (<1%). Dextrose is not protein bound.
97–99% (sex hormone-binding globulin and albumin)
Approximately 0.5-0.6 L/kg. Mannitol distributes primarily in extracellular fluid (ECF); it does not enter cells significantly. Clinically, this low Vd indicates confinement to ECF, important for osmotic effects.
0.3–0.6 L/kg; indicates distribution into lean muscle and sex organs
Intravenous: 100% bioavailability. Oral bioavailability is negligible (<10%) as mannitol is poorly absorbed and acts as an osmotic laxative; Dextrose is well absorbed orally (100%) but not relevant for this IV formulation.
Oral: <5% (methyltestosterone: ~20–25% due to 17α-alkylation); IM: 100%
Contraindicated in anuria or severe renal impairment (GFR < 20 m L/min). For GFR 20-50 m L/min, use with caution and monitor serum osmolality; reduce dose or extend interval. No specific dose reduction formula established.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, consider reducing dose or increasing interval; monitor for fluid retention and hypertension.
No specific adjustments required for hepatic impairment. Monitor fluid and electrolyte balance due to potential volume expansion.
Contraindicated in Child-Pugh class B or C cirrhosis. For mild hepatic impairment (Child-Pugh A), start with lower dose (e.g., 12.5 mg every 2 weeks) and titrate based on response and liver function.
0.25-1 g/kg (2.5-10 m L/kg of 10% solution) intravenously over 30-60 minutes, repeated as needed. Max dose 2 g/kg/day. Adjust based on response and serum osmolality.
Not recommended for use in pediatric patients (safety and efficacy not established). For male adolescents with hypogonadism, individualize: start at 12.5 mg every 2 weeks and adjust based on testosterone levels and growth.
Use lower initial doses and monitor renal function and electrolytes closely due to age-related decline in renal function and higher risk of volume overload. Start at 25-50 g (250-500 m L of 10% solution) and titrate.
Start with lower initial dose (e.g., 12.5 mg every 2 weeks); monitor prostate-specific antigen (PSA) and hematocrit frequently. Avoid in patients with prostate cancer or untreated sleep apnea.
None.
WARNING: Androgens are contraindicated in pregnancy due to masculinization of female fetus. Hepatotoxicity, including peliosis hepatis and hepatic neoplasms, has been reported with prolonged use.
Monitor serum electrolytes, osmolality, and renal function during therapy,May cause fluid and electrolyte imbalances, including hyponatremia or hypernatremia,Administer cautiously in patients with renal impairment, heart failure, or pulmonary edema,Use with caution in conditions where increased intravascular volume may be harmful,Do not administer if solution contains particulate matter or is discolored
Use with caution in patients with hepatic, renal, or cardiovascular disease; may cause gynecomastia, edema, hypercalcemia, and polycythemia; monitor liver function, lipid profile, and hematocrit periodically; may accelerate bone maturation in children; risk of prostate hypertrophy and urethral obstruction.
Anuria due to severe renal disease,Severe dehydration,Intracranial hemorrhage (unless during craniotomy),Active intracranial bleeding except during craniotomy,Hypersensitivity to mannitol or dextrose,Congestive heart failure,Pulmonary edema
Known or suspected prostate cancer; male breast cancer; pregnancy; lactation; hypersensitivity to methyltestosterone; severe hepatic impairment.
No clinically relevant food interactions.
Take with food containing fat (e.g., avocado, nuts, olive oil) to enhance absorption. Avoid grapefruit juice as it may increase testosterone levels via CYP3A4 inhibition. Limit alcohol due to potential liver effects.
No evidence of teratogenicity in animal studies; limited human data. Mannitol crosses the placenta; risk of fetal electrolyte disturbances and dehydration with maternal overdose. First trimester: theoretical risk only, no reported malformations. Second/third trimesters: monitor for maternal hyperosmolality and fluid shifts which may affect fetal hydration status.
Android 25 (methyltestosterone) is an androgen. First trimester: Virilization of female fetus, including clitoromegaly, labial fusion, urogenital sinus abnormalities if exposure occurs before 12 weeks gestation. Second and third trimesters: Continued risk of female pseudohermaphroditism, and potential for masculinization of female external genitalia. Androgens can cross the placenta and may also cause skeletal abnormalities and growth retardation. Pregnancy category X.
Not known if mannitol or dextrose are excreted in breast milk. Consider risk of osmotic diarrhea in neonate if present in milk. M/P ratio not established.
Methyltestosterone is excreted into breast milk; M/P ratio not established. May cause virilization in female infants and premature sexual development in male infants. Androgens can suppress lactation. Use during breastfeeding is contraindicated.
No specific dose adjustment recommended; monitor maternal fluid status closely as pregnancy increases risk of pulmonary edema; adjust rate based on urine output and osmolality.
Android 25 is contraindicated in pregnancy, so no dosing adjustments are applicable. If used inadvertently, discontinue immediately. No pharmacokinetic data to guide dose changes; avoid use entirely.
Monitor serum sodium and osmolality closely; risk of hypernatremia and acute kidney injury. Use an in-line filter to prevent crystallization. Administer by slow IV infusion to avoid fluid overload. Contraindicated in anuria and severe pulmonary edema.
Android 25 (testosterone undecanoate) requires absorption via lymphatic system; administer with fat-containing meal. Monitor serum testosterone levels 3-5 hours post-dose. Avoid in patients with breast cancer or known or suspected prostate cancer. Risk of polycythemia; check hematocrit before and during therapy.
Report any signs of fluid overload like shortness of breath or swelling.,This medicine may cause increased urination and thirst.,Do not take this medication by mouth; it is for intravenous use only.,Inform your healthcare provider if you have kidney problems or heart failure.
Take capsules with meals, especially those containing fat, to improve absorption.,Do not chew or crush capsules; swallow whole.,Report signs of deep vein thrombosis (leg swelling, pain) or pulmonary embolism (sudden dyspnea, chest pain).,Women of reproductive potential should avoid pregnancy; use effective contraception.,Keep out of reach of children; testosterone can cause serious harm if accidentally ingested.,Regular blood tests (testosterone, hematocrit, PSA, lipid profile) are required.
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER vs ANDROID 25, answered by our medical review team.
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER is a Osmotic Diuretic that works by Mannitol is an osmotic diuretic that increases plasma osmolality, drawing water from intracellular spaces into the extracellular fluid and bloodstream, thereby reducing cerebral edema and promoting diuresis. Dextrose provides a source of calories and may help prevent hypoglycemia.. ANDROID 25 is a Androgen that works by Android 25 contains methyltestosterone, a synthetic androgen that binds to androgen receptors, promoting protein synthesis and anabolic effects. It also inhibits gonadotropin secretion from the pituitary, reducing endogenous testosterone production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER and ANDROID 25 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER is: Adult: 50-100 g (500-1000 m L of 10% solution) intravenously over 1-2 hours, repeated as needed every 6-12 hours. Individualize based on urine output and serum osmolality.. The standard adult dose of ANDROID 25 is: Testosterone 25 mg subcutaneously or intramuscularly every 2 to 4 weeks. Alternatively, 125 mg intramuscularly every 10 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER and ANDROID 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER is classified as Category A/B. No evidence of teratogenicity in animal studies; limited human data. Mannitol crosses the placenta; risk of fetal electrolyte disturbances and dehydration with maternal overdose. F. ANDROID 25 is classified as Category C. Android 25 (methyltestosterone) is an androgen. First trimester: Virilization of female fetus, including clitoromegaly, labial fusion, urogenital sinus abnormalities if exposure oc. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.